Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo

References

• ChervinskyDBrecherMHoelcleMCremophor-EL enhances Taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell lineAnticancer Res19931393968097392
   PubMed Web of Science ®Google Scholar
• WebsterLLinsenmeyerMMillwardMMortonCBishopJWoodcockDMeasurement of Cremophor EL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotypeJ Natl Cancer Inst199385168516908105099
   PubMed Web of Science ®Google Scholar
• FjällskogMLFriiLBerghJIs Cremophor EL, solvent for paclitaxel, cytotoxic?Lancet1993342873
   PubMed Web of Science ®Google Scholar
• RowinskyEEisenhauerEChaudhryVArbuckSDonehowerRClinical toxicities encountered with paclitaxel (Taxol)Semin Oncol1993204 Suppl 31158102012
   PubMed Web of Science ®Google Scholar
• DorrRTPharmacology and toxicology of Cremophor EL diluentAnn Pharmacother1994285S11147915152
   PubMedGoogle Scholar
• GoldspielBRPharmaceutical issues: preparation, administration, stability, and compatibility with other medicationsAnn Pharmacother1994282326
   PubMedGoogle Scholar
• SongDHsuLFAuJLSBinding of Taxol to plastic and glass containers and protein under in vitro conditionsJ Pharm Sci19968529318926579
   PubMed Web of Science ®Google Scholar
• KongshaugMChengLSMoanJRimingtonCInteraction of Cremophor EL with human plasmaInt J Biochem1991234734782015955
   PubMedGoogle Scholar
• SykesEWoodburnKDeckerDKesselDEffects of Cremophor EL on distribution of Taxol to serum lipoproteinsBr J Cancer1994704014047915910
   PubMed Web of Science ®Google Scholar
• GaoJFGuanSDengWJClinical study of comparing LP and TP regimens in the treatment of advanced non-small cell lung cancerChinese-German J Clin Oncol20109198200
   Google Scholar
• ZhangQHuangXEGaoLLA clinical study on the premedication of paclitaxel liposome in the treatment of solid tumorsBiomed Pharmacother20096360360719019625
   PubMed Web of Science ®Google Scholar
• HolvoetCVanderHYLoriesGPreparation and evaluation of paclitaxel-containing liposomesPharmazie20076212613217341033
   PubMed Web of Science ®Google Scholar
• YangTCuiFDChaiMKLiposome formulation of paclitaxel with enhanced solubility and stabilityDrug Deliv20071430130817613018
   PubMed Web of Science ®Google Scholar
• StinchcombeTENanoparticle albumin-bound paclitaxel: a novel Cremophor EL-free formulation of paclitaxelNanomedicine (Lond)2007241542317716129
   PubMed Web of Science ®Google Scholar
• HureauxJLagarceFGagnadouxFLipid nanocapsules: ready-to- use nanovectors for the aerosol delivery of paclitaxelEur J Pharm Biopharm20097323924619560538
   PubMed Web of Science ®Google Scholar
• YangTChoiMKCuiFDAntitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cellsPharm Res2007242402241117828616
   PubMed Web of Science ®Google Scholar
• WeinerALLiposomes as carriers for polypeptidesAdv Drug Deliv Rev19893307341
   Google Scholar
• ZhaoPQWangHJYuMPaclitaxel-loaded, folic-acid-targeted and TAT-peptide-conjugated polymeric liposomes: in vitro and in vivo evaluationPharm Res2010271914192620582454
   PubMed Web of Science ®Google Scholar
• MengSYSuBLiWIntegrin-targeted paclitaxel nanoliposomes for tumor therapyMed Oncol2011281180118720645030
   PubMed Web of Science ®Google Scholar
• SharmaAMayhewEStraubingerRMAntitumor effect of Taxol-containing liposomes in a Taxol-resistant murine tumor modelCancer Res199353587758817903197
   PubMed Web of Science ®Google Scholar
• BalasubramanianSVStraubingerRMTaxol-lipid interactions: Taxol-dependent effects on the physical properties of model membranesBiochemistry199433894189477913831
   PubMed Web of Science ®Google Scholar
• SharmaASharmaUSStraubingerRMPaclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemiaCancer Lett19961072652728947523
   PubMed Web of Science ®Google Scholar
• LinYBXieRLinYZTherapeutic effect of paclitaxel liposome combined with cisplatin for III–IV degrees of cervical cancerChin J Woman Child Health Res (Chinese)200819571573
   Google Scholar
• ImmordinoMLDosioFCattelLStealth liposomes: review of the basic science, rationale, and clinical applications, existing and potentialInt J Nanomedicine2006129731517717971
   PubMed Web of Science ®Google Scholar
• TorchilinVPTrubetskoyVSWhich polymers can make nanoparticulate drug carriers long-circulating?Adv Drug Deliv Rev199516141155
   Web of Science ®Google Scholar
• KlibanovALMaruyamaKTorchilinVPHuangLAmphipathic polyethylene glycols effectively prolong the circulation time of liposomesFEBS Lett19902682352372384160
   PubMed Web of Science ®Google Scholar
• BlumeGCevcGMolecular mechanism of the lipid vesicle longevity in vivoBiochim Biophys Acta199311461571688452853
   PubMed Web of Science ®Google Scholar
• SeniorJDelgadoCFisherDTilcockCGregoriadisGInfluence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly (ethylene glycol)-coated vesiclesBiochim Biophys Acta1991106277821998713
   PubMed Web of Science ®Google Scholar
• ParkJLiposome-based drug delivery in breast cancer treatmentBreast Cancer Res20024959912052251
   PubMed Web of Science ®Google Scholar
• YangTCuiFDChoiMKEnhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluationInt J Pharm200733831732617368984
   PubMed Web of Science ®Google Scholar
• YoshizawaYKonoYOgawaraKPEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacyInt J Pharm201141213214121507344
   PubMed Web of Science ®Google Scholar
• CrosassoPCerutiMBrusaPArpiccoSDosioFCattelLPreparation, characterization and properties of sterically stabilized paclitaxel-containing liposomesJ Control Release200063193010640577
   PubMed Web of Science ®Google Scholar
• HuangYChenXMXiangBAntiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX): in vitro and in vivoAAPS Pharm Sci Tech201011752759
   PubMed Web of Science ®Google Scholar
• Penault-LlorcaFBertucciFAdélaïdeJExpression of FGF and FGF receptor genes in human breast cancerInt J Cancer1995611701767705943
   PubMed Web of Science ®Google Scholar
• DanielsenTRofstadEKVEGF, bFGF and EGF in the angiogenesis of human melanoma xenograftsInt J Cancer1998768368419626350
   PubMed Web of Science ®Google Scholar
• Kwabi-AddoBOzenMIttmannMThe role of fibroblast growth factors and their receptors in prostate cancerEndocr Relat Cancer20041170972415613447
   PubMed Web of Science ®Google Scholar
• HeQWeiYTianLInhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in miceJ Biol Chem2003278218312183612651849
   PubMed Web of Science ®Google Scholar
• ChenXWangXWangYImproved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptideJ Control Release2010145172520307599
   PubMed Web of Science ®Google Scholar
• CaiLQiuNLiXA novel truncated basic fibroblast growth factor fragment-conjugated poly (ethylene glycol)-cholesterol amphiphilic polymeric drug delivery system for targeting to the FGFR- overexpressing tumor cellsInt J Pharm201140817318221277964
   PubMed Web of Science ®Google Scholar
• SharmaAMayhewEBolcsakLActivity of paclitaxel liposome formulations against human ovarian tumor xenograftsInt J Cancer1997711031079096672
   PubMed Web of Science ®Google Scholar
• SavvaMDudaEHuangLA genetically modified recombinant tumor necrosis factor-α conjugated to the distal terminals of liposomal surface grafted polyethyleneglycol chainsInt J Pharm1999184455110425350
   PubMed Web of Science ®Google Scholar
• ReddWHMontgomeryGHDuHamelKNBehavioral intervention for cancer treatment side effectsJ Natl Cancer Inst20019381082311390531
   PubMed Web of Science ®Google Scholar
• CheongIHuangXBettegowdaCA bacterial protein enhances the release and efficacy of liposomal cancer drugsScience20063141308131117124324
   PubMed Web of Science ®Google Scholar
• Lotfi-JamKCareyMJeffordMSchofieldPCharlesonCArandaSNonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic reviewJ Clin Oncol2008265618562918981466
   PubMed Web of Science ®Google Scholar
• DharapSWangYChandnaPTumor-specific targeting of an anticancer drug delivery system by LHRH peptideProc Natl Acad Sci U S A2005102129621296716123131
   PubMed Web of Science ®Google Scholar
• MoghimiSMHunterACMurrayJCNanomedicine: current status and future prospectsFASEB J20051931133015746175
   PubMed Web of Science ®Google Scholar
• SuoTGeWZhangJZ17 cases of advanced non-small cell lung cancer treated with paclitaxel liposome plus nedaplatinChinese- German Journal of Clinical Oncology201211196198
   Google Scholar
• TorchilinVPLevchenkoTSRammohanRPapahadjopoulos-SternbergBD’SouzaGGCell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexesProc Natl Acad Sci U S A20031001972197712571356
   PubMed Web of Science ®Google Scholar
• YuWPirolloKFYuBEnhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptideNucleic Acids Res2004325e4815026537
   PubMed Web of Science ®Google Scholar
• KawakamiKKawakamiMPuriRKIL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancerJ Immunol20021697119712612471149
   PubMed Web of Science ®Google Scholar
• NakaseMInuiMOkumuraKKameiTNakamuraSTagawaTp53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposomeMol Cancer Ther2005462563115827336
   PubMed Web of Science ®Google Scholar
• MoghimiSMHunterACMurrayJCLong-circulating and target-specific nanoparticles: theory to practicePharmacol Rev20015328331811356986
   PubMed Web of Science ®Google Scholar
• SeniorJGregoriadisGIs half-life of circulating liposomes determined by changes in their permeability?FEBS Lett19821451091146897042
   PubMed Web of Science ®Google Scholar
• VolanakisJEWirtzKWAInteraction of C-reactive protein with artificial phosphatidylcholine bilayersNature1979281155157471064
   PubMed Web of Science ®Google Scholar
• ChonnACullisPDevineDThe role of surface charge in the activation of the classical and alternative pathways of complement by liposomesJ Immunol1991146423442412040798
   PubMed Web of Science ®Google Scholar
• DevineDVBradleyAJThe complement system in liposome clearance: can complement deposition be inhibited?Adv Drug Deliv Rev199832192910837633
   PubMed Web of Science ®Google Scholar
• LundbergBRisovicVRamaswamyMWasanKA lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administrationJ Control Release2003869310012490375
   PubMed Web of Science ®Google Scholar
• GabizonAHorowitzATGorenDTargeting folate receptor with folate linked to extremities of poly (ethylene glycol)-grafted liposomes: in vitro studiesBioconjug Chem19991028929810077479
   PubMed Web of Science ®Google Scholar
• LeeRJLowPSFolate-mediated tumor cell targeting of liposome- entrapped doxorubicin in vitroBiochim Biophys Acta199512331341447865538
   PubMed Web of Science ®Google Scholar
• GustafsonDLMerzALLongMEPharmacokinetics of combined doxorubicin and paclitaxel in miceCancer Lett200522016116915766591
   PubMed Web of Science ®Google Scholar